uniQure N.V., commonly known as QURE, is a biopharmaceutical company that has been leading pioneers in the development of gene therapies, with a specific focus on treating patients who have severe genetic disorders. The company was founded in Amsterdam, the Netherlands, in 1998, and has since grown to have operations in Lexington, Massachusetts, and Leiden, in the Netherlands.
uniQure N.V is prominently known for bringing the first-ever gene therapy to market. Its distinguishable works lie in the development and delivery of innovative, one-time, potentially curative treatments for numerous patients around the globe who otherwise have limited treatment options.
uniQure utilizes the human adeno-associated virus (AAV) - a harmless virus that is naturally occurring in humans - as a vector in its gene therapy approach. The goal here is to precisely target particular disease-associated genes in specific tissues in the body and replace defective versions with functional copies, thus offering a lasting cure for these terrible illnesses.
The medium-to-long term vision of uniQure is developing a pipeline of gene therapies to treat a number of severe genetic diseases. This includes haemophilia B, a rare, inherited disorder where the blood does not clot properly, for which the company developed the experimental gene therapy etranacogene dezaparvovec. uniQure is also engaged in the development of AMT-130, a gene therapy candidate for the treatment of Huntington's disease, a fatal, inherited neurodegenerative disorder.
uniQure N.V. demonstrates excellent scientific and technical expertise, positioning itself as a considerable player in the expanding field of gene-based medicine. Its technological platform has the potential to revolutionize the way we approach genetic disorders and allow for the creation of groundbreaking therapies that provide a cure rather than ongoing management of symptoms.
Despite the many challenges inherent in developing gene-based therapies, uniQure’s ongoing commitment to innovation, preclinical, and clinical excellence keeps the company at the forefront of this important field in genetic medicine. uniQure continues its quest to deliver on the promise of gene therapy to empower self-healing and make a significant difference in the lives of patients with genetic disorders.
In essence, uniQure is not just about pioneering gene therapies. It's about providing hope for families and individuals for whom traditional medicine might not have an answer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Uniqure N.v. (NASDAQ: QURE) using AI models to provide real-time signals and trading strategies. It highlights weak near- and mid-term sentiment, a neutral long-term outlook, and details a significant short setup. The piece offers specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies across different time horizons.
UniQure is preparing to release four-year results for its Huntington's disease gene therapy, AMT-130, by the end of September. The biotech company has already submitted the drug to regulators in the U.S. and U.K. Previous three-year data indicated that a high dose of AMT-130 slowed the progression of Huntington's by 75% compared to an external control group.
This article from Stock Traders Daily provides a liquidity mapping analysis for Uniqure N.v. (NASDAQ: QURE), highlighting a weak near-term sentiment that could lead to bearish positioning. It details an exceptional short setup with a high risk-reward ratio and outlines three distinct AI-generated trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, identifying support and resistance levels.
uniQure has submitted a Biologics License Application (BLA) to the FDA and a Marketing Authorisation Application (MAA) to the UK's MHRA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease. These submissions are based on three-year Phase I/II clinical trial data, which showed a significant slowing of disease progression in treated patients compared to controls. If approved, AMT-130 would be the first disease-modifying treatment for Huntington's disease, a condition currently without therapies to slow its progression.
uniQure N.V. (QURE) has submitted a Biologics License Application (BLA) to the FDA for accelerated approval of its investigational gene therapy, ifezuntirgene inilparvovec (AMT-130), for Huntington's disease, and has requested Priority Review. Concurrently, the company also submitted a Marketing Authorization Application (MAA) for AMT-130 to the UK's regulatory agency. This marks a significant step forward after a previous regulatory setback, with the applications supported by three-year data from phase I/II clinical studies.
uniQure (QURE) shares have risen 17.5% since its last earnings report, outperforming the S&P 500 despite missing Q2 2026 estimates with a wider loss due to higher costs, although revenues increased year-over-year. The company's pipeline, particularly AMT-130 for Huntington's disease, shows significant regulatory progress, with a BLA submission expected in Q3 2026. While estimates for QURE have been trending upward, the stock currently holds a Zacks Rank #3 (Hold) and a poor VGM Score of F.